The use of oxybutynin for treating facial hyperhidrosis

Anais Brasileiros de Dermatologia

Nelson Wolosker²  José Ribas Milanez De Campos¹  Paulo Kauffman¹  Marco Antonio Munia²  Samantha Neves¹  Fábio Biscegli Jatene¹  Pedro Puech-leão¹ 

[1] ,University of Sao Paulo College of Medicine Sao Paulo SP ,Brazil

关键词: Advanced treatment;    Clinical protocols;    Hyperhidrosis;    Indicators of quality of life;    Sympathectomy;    Sweating;    Hiperidrose;    Indicadores de qualidade de vida;    Protocolos clínicos;    Simpatectomia;    Sudorese;    Tratamento avançado;   

DOI  :  10.1590/S0365-05962011000300005

来源: SciELO

【 摘 要 】

BACKGROUND: Facial hyperhidrosis is a disease that may lead patients to serious emotional disturbances. Video-assisted thoracic sympathectomy provides excellent resolution of facial hyperhidrosis, but is associated with certain complications. The most frequent and important complication is compensatory hyperhidrosis. Especially in patients who have undergone resection of the second thoracic ganglion, the risk of severe compensatory hyperhidrosis is higher, which may cause dissatisfaction with the procedure. OBJECTIVE: The aim of this study was to evaluate the efficacy of the use of low doses of oxybutynin in treating facial hyperhidrosis as well as the level of patient satisfaction with its use. METHODS: 25 patients with facial hyperhidrosis were treated with oxybutynin. The patients underwent 2 evaluations: before and after treatment. These evaluations were used to assess the patients' clinical improvement and quality of life. RESULTS: We observed that more than 75% of the patients evolved with an improvement in facial hyperhidrosis, and 52% of them presented a great improvement. CONCLUSION: Treatment of facial hyperhidrosis with oxybutynin is a good alternative to sympathectomy, since it presents good results and improves quality of life, in addition to not exposing patients to the risk of experiencing the side effects of sympathectomy

【 授权许可】

CC BY-NC   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License